Liangliang Hao | Profiles RNS

Liangliang Hao, PhD

Assistant Professor

Boston University College of Engineering

Biomedical Engineering

PhD, Northwestern University
MS, University of Waterloo
BS, Nankai University

Websites

	LinkedIn
	Hao Lab
	BU College of Engineering Profile
	Google Scholar
	MIT Office of Innovation Profile
	ResearchGate

ORCID : 0000-0001-7513-3922

Precision medicine has transformative impact in managing heterogeneous disorders including cancer, metabolic, and neurological diseases. At the living interface of precision engineering and health, the Hao laboratory will develop molecular and cellular tools to precisely track and control disease biology in intact organisms. Our specific research interests include (1) noninvasive disease detection and treatment monitoring at the Point-of-Care, (2) tissue-specific transcriptome engineering, and (3) multimodal systemic imaging. These projects will shed light on the dynamic interplay of diseased cells and their microenvironment. We seek to use these insights to address grand challenges of getting precision medicine into healthcare practice such as comorbidities, timely interventions, and access in low-resource areas.

BU Research
NIH RePORTER Research

Developing multiplexed microenvironmental sensors for precision diagnostics of cancer metastasis
03/01/2023 - 02/28/2026 (PI)
NIH/National Cancer Institute
4R00CA237861-03

CRISPR-Cas-amplified biomarkers for disease detection and monitoring at the point of care
11/01/2023 - 10/31/2024 (PI)
PhRMA Foundation

Title

Yr	Title	Project-Sub Proj
2024	Developing multiplexed microenvironmental sensors for precision diagnostics of cancer metastasis	5R00CA237861-04
2023	Developing multiplexed microenvironmental sensors for precision diagnostics of cancer metastasis	4R00CA237861-03
2021	Developing multiplexed microenvironmental sensors for precision diagnostics of cancer metastasis	5K99CA237861-02
2020	Developing multiplexed microenvironmental sensors for precision diagnostics of cancer metastasis	1K99CA237861-01A1

Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

iCite Analysis Copy PMIDs To Clipboard

Hao L, Zhao RT, Welch NL, Tan EKW, Zhong Q, Harzallah NS, Ngambenjawong C, Ko H, Fleming HE, Sabeti PC, Bhatia SN. CRISPR-Cas-amplified urinary biomarkers for multiplexed and portable cancer diagnostics. Nat Nanotechnol. 2023 Jul; 18(7):798-807. PMID: 37095220; PMCID: PMC10359190; DOI: 10.1038/s41565-023-01372-9;

Hao L, Rohani N, Zhao RT, Pulver EM, Mak H, Kelada OJ, Ko H, Fleming HE, Gertler FB, Bhatia SN. Microenvironment-triggered multimodal precision diagnostics. Nat Mater. 2021 Oct; 20(10):1440-1448. PMID: 34267368; DOI: 10.1038/s41563-021-01042-y;

Hao L, Zhao RT, Ngambenjawong C, Fleming HE, Bhatia S. CRISPR-Cas-amplified urine biomarkers for multiplexed and portable cancer diagnostics. bioRxiv. 2020. View Publication

Tian C, Öhlund D, Rickelt S, Lidström T, Huang Y, Hao L, Zhao RT, Franklin O, Bhatia SN, Tuveson DA, Hynes RO. Cancer Cell-Derived Matrisome Proteins Promote Metastasis in Pancreatic Ductal Adenocarcinoma. Cancer Res. 2020 Apr 01; 80(7):1461-1474. PMID: 32029550; PMCID: PMC7127978; DOI: 10.1158/0008-5472.CAN-19-2578;

Boehnke N, Correa S, Hao L, Wang W, Straehla JP, Bhatia SN, Hammond PT. Theranostic Layer-by-Layer Nanoparticles for Simultaneous Tumor Detection and Gene Silencing. Angew Chem Int Ed Engl. 2020 Feb 10; 59(7):2776-2783. PMID: 31747099; PMCID: PMC7002217; DOI: 10.1002/anie.201911762;

Gilles ME, Hao L, Brown K, Lim J, Bhatia SN, Slack FJ. Tumor penetrating nanomedicine targeting both an oncomiR and an oncogene in pancreatic cancer. Oncotarget. 2019 Sep 03; 10(51):5349-5358. PMID: 31523393; PMCID: PMC6731108; DOI: 10.18632/oncotarget.27160;

Rohani N, Hao L, Alexis MS, Joughin BA, Krismer K, Moufarrej MN, Soltis AR, Lauffenburger DA, Yaffe MB, Burge CB, Bhatia SN, Gertler FB. Acidification of Tumor at Stromal Boundaries Drives Transcriptome Alterations Associated with Aggressive Phenotypes. Cancer Res. 2019 Apr 15; 79(8):1952-1966. PMID: 30755444; PMCID: PMC6467770; DOI: 10.1158/0008-5472.CAN-18-1604;

Lo JH, Hao L, Muzumdar MD, Raghavan S, Kwon EJ, Pulver EM, Hsu F, Aguirre AJ, Wolpin BM, Fuchs CS, Hahn WC, Jacks T, Bhatia SN. iRGD-guided Tumor-penetrating Nanocomplexes for Therapeutic siRNA Delivery to Pancreatic Cancer. Mol Cancer Ther. 2018 Nov; 17(11):2377-2388. PMID: 30097486; PMCID: PMC6298224; DOI: 10.1158/1535-7163.MCT-17-1090;

Gilles ME, Hao L, Huang L, Rupaimoole R, Lopez-Casas PP, Pulver E, Jeong JC, Muthuswamy SK, Hidalgo M, Bhatia SN, Slack FJ. Personalized RNA Medicine for Pancreatic Cancer. Clin Cancer Res. 2018 Apr 01; 24(7):1734-1747. PMID: 29330203; DOI: 10.1158/1078-0432.CCR-17-2733;

Hao L, Lo J, Bhatia S. Tumor penetrating RNA delivery for therapeutic benefit of pancreatic cancer. Cancer Research. 2017; 77(13_Suppl):5088.

Showing 10 of 32 results. Show More

Sprangers AJ, Hao L, Banga RJ, Mirkin CA. Liposomal Spherical Nucleic Acids for Regulating Long Noncoding RNAs in the Nucleus. Small. 2017 Mar; 13(10). PMID: 28026123; PMCID: PMC5343594; DOI: 10.1002/smll.201602753;

Wang X, Hao L, Bu HF, Scott AW, Tian K, Liu F, De Plaen IG, Liu Y, Mirkin CA, Tan XD. Spherical nucleic acid targeting microRNA-99b enhances intestinal MFG-E8 gene expression and restores enterocyte migration in lipopolysaccharide-induced septic mice. Sci Rep. 2016 Aug 19; 6:31687. PMID: 27538453; PMCID: PMC4990839; DOI: 10.1038/srep31687;

Zhang C, Hao L, Calabrese CM, Zhou Y, Choi CH, Xing H, Mirkin CA. Biodegradable DNA-Brush Block Copolymer Spherical Nucleic Acids Enable Transfection Agent-Free Intracellular Gene Regulation. Small. 2015 Oct 28; 11(40):5360-8. PMID: 26297167; PMCID: PMC4710492; DOI: 10.1002/smll.201501573;

Rouge JL, Sita TL, Hao L, Kouri FM, Briley WE, Stegh AH, Mirkin CA. Ribozyme-Spherical Nucleic Acids. J Am Chem Soc. 2015 Aug 26; 137(33):10528-10531. PMID: 26271335; PMCID: PMC4666730; DOI: 10.1021/jacs.5b07104;

Narayan SP, Choi CH, Hao L, Calabrese CM, Auyeung E, Zhang C, Goor OJ, Mirkin CA. The Sequence-Specific Cellular Uptake of Spherical Nucleic Acid Nanoparticle Conjugates. Small. 2015 Sep 02; 11(33):4173-82. PMID: 26097111; PMCID: PMC4560454; DOI: 10.1002/smll.201500027;

Kouri FM, Hurley LA, Daniel WL, Day ES, Hua Y, Hao L, Peng CY, Merkel TJ, Queisser MA, Ritner C, Zhang H, James CD, Sznajder JI, Chin L, Giljohann DA, Kessler JA, Peter ME, Mirkin CA, Stegh AH. miR-182 integrates apoptosis, growth, and differentiation programs in glioblastoma. Genes Dev. 2015 Apr 01; 29(7):732-45. PMID: 25838542; PMCID: PMC4387715; DOI: 10.1101/gad.257394.114;

Radovic-Moreno AF, Chernyak N, Mader CC, Nallagatla S, Kang RS, Hao L, Walker DA, Halo TL, Merkel TJ, Rische CH, Anantatmula S, Burkhart M, Mirkin CA, Gryaznov SM. Immunomodulatory spherical nucleic acids. Proc Natl Acad Sci U S A. 2015 Mar 31; 112(13):3892-7. PMID: 25775582; PMCID: PMC4386353; DOI: 10.1073/pnas.1502850112;

Rouge JL, Hao L, Wu XA, Briley WE, Mirkin CA. Spherical nucleic acids as a divergent platform for synthesizing RNA-nanoparticle conjugates through enzymatic ligation. ACS Nano. 2014 Sep 23; 8(9):8837-43. PMID: 25144723; PMCID: PMC4174098; DOI: 10.1021/nn503601s;

Wu XA, Choi CH, Zhang C, Hao L, Mirkin CA. Intracellular fate of spherical nucleic acid nanoparticle conjugates. J Am Chem Soc. 2014 May 28; 136(21):7726-33. PMID: 24841494; PMCID: PMC4046773; DOI: 10.1021/ja503010a;

Zhang C, Macfarlane RJ, Young KL, Choi CH, Hao L, Auyeung E, Liu G, Zhou X, Mirkin CA. A general approach to DNA-programmable atom equivalents. Nat Mater. 2013 Aug; 12(8):741-6. PMID: 23685863; DOI: 10.1038/nmat3647;

Choi CH, Hao L, Narayan SP, Auyeung E, Mirkin CA. Mechanism for the endocytosis of spherical nucleic acid nanoparticle conjugates. Proc Natl Acad Sci U S A. 2013 May 07; 110(19):7625-30. PMID: 23613589; PMCID: PMC3651452; DOI: 10.1073/pnas.1305804110;

Zhang K, Hao L, Hurst SJ, Mirkin CA. Antibody-linked spherical nucleic acids for cellular targeting. J Am Chem Soc. 2012 Oct 10; 134(40):16488-91. PMID: 23020598; PMCID: PMC3501255; DOI: 10.1021/ja306854d;

Peng H, Kaplan N, Hamanaka RB, Katsnelson J, Blatt H, Yang W, Hao L, Bryar PJ, Johnson RS, Getsios S, Chandel NS, Lavker RM. microRNA-31/factor-inhibiting hypoxia-inducible factor 1 nexus regulates keratinocyte differentiation. Proc Natl Acad Sci U S A. 2012 Aug 28; 109(35):14030-4. PMID: 22891326; PMCID: PMC3435188; DOI: 10.1073/pnas.1111292109;

Young KL, Scott AW, Hao L, Mirkin SE, Liu G, Mirkin CA. Hollow spherical nucleic acids for intracellular gene regulation based upon biocompatible silica shells. Nano Lett. 2012 Jul 11; 12(7):3867-71. PMID: 22725653; PMCID: PMC3397824; DOI: 10.1021/nl3020846;

Wang M, Wang C, Young KL, Hao L, Medved M, Rajh T, Fry HC, Zhu L, Karczmar S, Watson C, Jiang JS, Markovic NM, Stamenkovic VR. Cross-linked Heterogeneous Nanoparticles as Bifunctional Probe. Chemistry of Materials. 2012; 24(13):2423-2425. View Publication

Peng H, Hamanaka RB, Katsnelson J, Hao LL, Yang W, Chandel NS, Lavker RM. MicroRNA-31 targets FIH-1 to positively regulate corneal epithelial glycogen metabolism. FASEB J. 2012 Aug; 26(8):3140-7. PMID: 22532441; PMCID: PMC3405266; DOI: 10.1096/fj.11-198515;

Giam LR, Massich MD, Hao L, Shin Wong L, Mader CC, Mirkin CA. Scanning probe-enabled nanocombinatorics define the relationship between fibronectin feature size and stem cell fate. Proc Natl Acad Sci U S A. 2012 Mar 20; 109(12):4377-82. PMID: 22392973; PMCID: PMC3311369; DOI: 10.1073/pnas.1201086109;

Zhang K, Zheng D, Hao L, Cutler JI, Auyeung E, Mirkin CA. Immunopods: polymer shells with native antibody cross-links. Angew Chem Int Ed Engl. 2012 Jan 27; 51(5):1169-72. PMID: 22173847; PMCID: PMC3930230; DOI: 10.1002/anie.201106313;

Hao L, Patel PC, Alhasan AH, Giljohann DA, Mirkin CA. Nucleic acid-gold nanoparticle conjugates as mimics of microRNA. Small. 2011 Nov 18; 7(22):3158-62. PMID: 21922667; PMCID: PMC3681955; DOI: 10.1002/smll.201101018;

Patel PC, Hao L, Yeung WS, Mirkin CA. Duplex end breathing determines serum stability and intracellular potency of siRNA-Au NPs. Mol Pharm. 2011 Aug 01; 8(4):1285-91. PMID: 21630673; PMCID: PMC3200553; DOI: 10.1021/mp200084y;

Yu HQ, Hao LL. [Research progress of normal physical functions of prion protein (PrPc)]. Sheng Li Ke Xue Jin Zhan. 2006 Oct; 37(4):369-72. PMID: 17262976

Weng HL, Cai WM, Wang BE, Jia JD, Zhou XQ, Shi DM, Zhang DF, Zhao YR, Hao LJ, Wang SY, Wu WF, Xian JZ. [Clinical study of anti-hepatic fibrosis effect of IFN-gamma in patients with chronic hepatitis B]. Zhonghua Yi Xue Za Zhi. 2003 Jun 10; 83(11):943-7. PMID: 12899793

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 32 publications over 14 distinct years, with a maximum of 6 publications in 2012